이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

TrivarX 관리

관리 기준 확인 0/4

현재 CEO에 대한 정보가 충분하지 않습니다.

주요 정보

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	no data
CEO 소유권	n/a
경영진 평균 재임 기간	1.2yrs
이사회 평균 재임 기간	2.8yrs

최근 관리 업데이트

Recent updates

CEO

TrivarX 에는 CEO가 없거나 그에 대한 데이터가 없습니다.

리더십 팀

이름	위치	테뉴어	보상	소유권
Kai Sun	Chief Operating Officer	less than a year	데이터 없음	데이터 없음
Josh Purdy	Public Relations Director	no data	데이터 없음	데이터 없음
Archie Defillo	Chief Medical Officer	no data	데이터 없음	데이터 없음
Massimiliano Grassi	Head of Artificial Intelligence	4.4yrs	데이터 없음	데이터 없음
Stephen Buckley	Company Secretary	1.2yrs	데이터 없음	데이터 없음

1.2yrs

평균 재임 기간

경험이 풍부한 관리: TRI 의 관리팀은 경험 (평균 재직 기간 1.2 년)으로 간주되지 않으므로 새로운 팀을 추천합니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Christopher Ntoumenopoulos	Non-Executive Director	1.3yrs	AU$22.89k	1.04% A$ 106.6k
Peter Carlisle	Chairman of Growth & Advocacy Advisory Board	7yrs	AU$48.02k	데이터 없음
Patrick Kennedy	Member of Growth & Advocacy Advisory Board	4.8yrs	데이터 없음	데이터 없음
Michael Phelps	Member of Growth & Advocacy Advisory Board	4.8yrs	데이터 없음	데이터 없음
David Trimboli	Independent Non-Executive Chairman	1.8yrs	AU$61.79k	데이터 없음
Elizabeth Lombardo	Member of Growth & Advocacy Advisory Board	2.8yrs	데이터 없음	데이터 없음
Thomas Young	Non-Executive Director	1.2yrs	AU$138.26k	데이터 없음

2.8yrs

평균 재임 기간

경험이 풍부한 이사회: TRI 의 이사회는 경험(평균 재직 기간 2.8 년)으로 간주되지 않으므로 새 이사회가 필요합니다.

TrivarX 관리

관리 기준 확인 0/4

주요 정보

최근 관리 업데이트

Medibio Limited, Annual General Meeting, Nov 29, 2023

Medibio Limited, Annual General Meeting, Oct 06, 2023

Medibio Limited Appoints Christopher Ntoumenopoulos as Director

Less than half of directors are independent

Medibio Limited Announces Resignation of Stephen Mitchley as a Director

Medibio Limited Appoints David Trimboli as the Company's New Non-Executive Chair

Recent updates

TrivarX Limited has filed a Follow-on Equity Offering in the amount of AUD 2.5 million.

Medibio Limited, Annual General Meeting, Nov 29, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

Medibio Limited, Annual General Meeting, Oct 06, 2023

Full year 2023 earnings released: AU$0.001 loss per share (vs AU$0.006 loss in FY 2022)

New minor risk - Financial data availability

First half 2023 earnings released

Medibio Limited Appoints Christopher Ntoumenopoulos as Director

Less than half of directors are independent

Medibio Limited Announces Resignation of Stephen Mitchley as a Director

Medibio Limited Appoints David Trimboli as the Company's New Non-Executive Chair

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Limited, Annual General Meeting, Nov 11, 2022

Medibio Limited Appoints Thomas R. Young as CEO

Full year 2022 earnings released: AU$0.006 loss per share (vs AU$0.001 loss in FY 2021)

Medibio Appoints David Trimboli to Its Board of Directors as Non-Executive Director

Medibio Limited Announces Sleep Analysis Depressive Burden Study Clinical Trial Commencement

Medibio Limited Announces Resignation of Claude Solitario as Managing Director

Medibio Limited Announces Executive Changes

Medibio Limited Announces That A DSM-V1 Diagnosis Will Be Included as Primary Comparator for the Purposes of Assessing the Efficacy of Its Depression Algorithms, MEB-001

Less than half of directors are independent

Medibio Limited Appoints Matt Mesnik as Non-Executive Director

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Medibio Limited Appoints Stephen Mitchley as Non-Executive Director

Full year 2021 earnings released: AU$0.001 loss per share (vs AU$0.004 loss in FY 2020)

Medibio Limited to Resubmit FDA 510(K) Application for its Sleep Staging Software, MEBbsleep

First half 2021 earnings released: AU$0.001 loss per share (vs AU$0.003 loss in 1H 2020)

Medibio Limited, Annual General Meeting, Mar 24, 2021

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 3 million.

Medibio Limited Receives CE Mark Approval for Its Sleep Staging Software, MEBsleep

Medibio Limited Commences the Initial Phase of Testing of its Consumer Mental Health App

Medibio Limited Announces US FDA Advises Further Data Needed for Mebsleep Approval

Medibio Limited Signs Global Master License & Services Agreement with Compass Group Plc

Medibio Limited Signs Clinical Trial Agreement with MedBridge Healthcare

Medibio Limited Submits Request for FDA Breakthrough Device Designation

Full year earnings released - AU$0.0044 loss per share

Full year earnings released - AU$0.0044 loss per share

Medibio Limited has completed a Follow-on Equity Offering in the amount of AUD 1.517195 million.

CEO

리더십 팀

평균 재임 기간

이사회 구성원

평균 재임 기간